{"title":"COVID 后神经认知障碍及其与白细胞介素的关系:一项基于医院的横断面研究","authors":"Ajmal Anjum, Arshad Hussain","doi":"10.1177/02537176241249373","DOIUrl":null,"url":null,"abstract":"The aim of this study was to determine the relationship between post-COVID neurocognitive symptoms and interleukin-6 levels. This was a hospital-based cross-sectional study wherein patients complaining of forgetfulness post-infection with coronavirus disease-2019 (COVID-19) were taken up for study ( n = 53) from February 2023 to June 2023. The forgetfulness was characterized using the memory subscale of Postgraduate Institute-Battery of Brain Dysfunction (PGI-BBD). In addition, sociodemographic data were collected from patients. After obtaining written informed consent, 3 mL of peripheral venous blood was collected from patients, and interleukin-6 levels were measured. Other inflammatory markers, like C-reactive protein (CRP), were also measured. The mean age of participants was 46.11 ± 8.58 years. Twenty-nine (54.72%) respondents were female, and 24 (45.28%) were male. Most (62.2%) of the patients in the study suffered from mild-to-moderate severity of COVID-19 infection. Among these patients, 43.3% had impairment in recent memory, 32 patients (60.3%) had impairment in attention and concentration, 54.7% had impairment in delayed recall, and 33.9% had impairment in immediate recall. Impairment in delayed recall was associated with a raised level of interleukin-6 ( P = .0048 [ P < .05]). Patients with impaired recall on PGI-BBD post-infection with COVID-19 have raised levels of interleukin-6, suggesting the role of neuroinflammation in post-COVID neurocognitive symptoms. Interleukin-6 is a marker of neuroinflammation that has been linked to cognitive decline in various studies. It can be used to predict cognitive decline and also aid in diagnosis.","PeriodicalId":13476,"journal":{"name":"Indian Journal of Psychological Medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Post-COVID Neurocognitive Disorder and Its Relation with Interleukin: A Hospital-based Cross-sectional Study\",\"authors\":\"Ajmal Anjum, Arshad Hussain\",\"doi\":\"10.1177/02537176241249373\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim of this study was to determine the relationship between post-COVID neurocognitive symptoms and interleukin-6 levels. This was a hospital-based cross-sectional study wherein patients complaining of forgetfulness post-infection with coronavirus disease-2019 (COVID-19) were taken up for study ( n = 53) from February 2023 to June 2023. The forgetfulness was characterized using the memory subscale of Postgraduate Institute-Battery of Brain Dysfunction (PGI-BBD). In addition, sociodemographic data were collected from patients. After obtaining written informed consent, 3 mL of peripheral venous blood was collected from patients, and interleukin-6 levels were measured. Other inflammatory markers, like C-reactive protein (CRP), were also measured. The mean age of participants was 46.11 ± 8.58 years. Twenty-nine (54.72%) respondents were female, and 24 (45.28%) were male. Most (62.2%) of the patients in the study suffered from mild-to-moderate severity of COVID-19 infection. Among these patients, 43.3% had impairment in recent memory, 32 patients (60.3%) had impairment in attention and concentration, 54.7% had impairment in delayed recall, and 33.9% had impairment in immediate recall. Impairment in delayed recall was associated with a raised level of interleukin-6 ( P = .0048 [ P < .05]). Patients with impaired recall on PGI-BBD post-infection with COVID-19 have raised levels of interleukin-6, suggesting the role of neuroinflammation in post-COVID neurocognitive symptoms. Interleukin-6 is a marker of neuroinflammation that has been linked to cognitive decline in various studies. It can be used to predict cognitive decline and also aid in diagnosis.\",\"PeriodicalId\":13476,\"journal\":{\"name\":\"Indian Journal of Psychological Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Psychological Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/02537176241249373\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Psychological Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02537176241249373","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Post-COVID Neurocognitive Disorder and Its Relation with Interleukin: A Hospital-based Cross-sectional Study
The aim of this study was to determine the relationship between post-COVID neurocognitive symptoms and interleukin-6 levels. This was a hospital-based cross-sectional study wherein patients complaining of forgetfulness post-infection with coronavirus disease-2019 (COVID-19) were taken up for study ( n = 53) from February 2023 to June 2023. The forgetfulness was characterized using the memory subscale of Postgraduate Institute-Battery of Brain Dysfunction (PGI-BBD). In addition, sociodemographic data were collected from patients. After obtaining written informed consent, 3 mL of peripheral venous blood was collected from patients, and interleukin-6 levels were measured. Other inflammatory markers, like C-reactive protein (CRP), were also measured. The mean age of participants was 46.11 ± 8.58 years. Twenty-nine (54.72%) respondents were female, and 24 (45.28%) were male. Most (62.2%) of the patients in the study suffered from mild-to-moderate severity of COVID-19 infection. Among these patients, 43.3% had impairment in recent memory, 32 patients (60.3%) had impairment in attention and concentration, 54.7% had impairment in delayed recall, and 33.9% had impairment in immediate recall. Impairment in delayed recall was associated with a raised level of interleukin-6 ( P = .0048 [ P < .05]). Patients with impaired recall on PGI-BBD post-infection with COVID-19 have raised levels of interleukin-6, suggesting the role of neuroinflammation in post-COVID neurocognitive symptoms. Interleukin-6 is a marker of neuroinflammation that has been linked to cognitive decline in various studies. It can be used to predict cognitive decline and also aid in diagnosis.
期刊介绍:
The Indian Journal of Psychological Medicine (ISSN 0253-7176) was started in 1978 as the official publication of the Indian Psychiatric Society South Zonal Branch. The journal allows free access (Open Access) and is published Bimonthly. The Journal includes but is not limited to review articles, original research, opinions, and letters. The Editor and publisher accept no legal responsibility for any opinions, omissions or errors by the authors, nor do they approve of any product advertised within the journal.